Cigna Medical & Pharmacy Policy Updates – November 2018

Click here to view the Cigna Medical & Pharmacy Policy Updates »

November 2018 Cigna Medical & Pharmacy Policy Policy Updates:

• Diagnostic Microbe Testing for Sexually Transmitted Diseases (STD) – (0530)
• Stem Cell Transplantation: Blood Cancers – (0533)
• Bone Mineral Density Measurement – (0300)
• Intraoperative Monitoring – (0509)
• Myoelectric Devices: Upper Limb – (0233)
• Omnibus Codes – (0504)
• Transcatheter Heart Valve Procedures – (0501)
• Nerve Conduction Velocity Studies – (0117)
• Somatosensory Evoked Potentials – (0122)
• Spinal Ultrasound – (0246)
• Stem-Cell Transplantation for Acute Lymphocytic /Lymphoblastic Leukemia – (0163)
• Stem-Cell Transplantation for Acute Myelogenous Leukemia – (0164)
• Stem-Cell Transplantation for Chronic Myelogenous Leukemia and Chronic Lymphocytic Leukemia – (0242)
• Stem-Cell Transplantation for Chronic Myelomonocytic Leukemia (CMML) and Juvenile Myelomonocytic Leukemia (JMML) – (0243)
• Stem-Cell Transplantation for Hodgkin Disease – (0188)
• Stem-Cell Transplantation for Multiple Myeloma, POEMS Syndrome and Amyloidosis – (0294)
• Stem-Cell Transplantation for Myelodysplastic Syndrome – (0187)
• Stem-Cell Transplantation for Non-Hodgkin Lymphoma – (0263)
• Electrodiagnostic Testing (EMG/NCV) – (CPG 129),
• Physical Performance Test or Measurement – (CPG 295),
• Spinal Ultrasound – (CPG 038)
• Cigna-eviCore Cobranded Imaging Guidelines:
• Calcitonin Gene-Related Peptide (CGRP) Inhibitors – (1813)
• Cannabidiol – (1814)
• Etelcalcetide – (1812)
• Nitrofurantoin Suspension – (P0059)
• Antiemetic Therapy – (1705)
• Belimumab – (1114)
• Clotting Factors and Antithrombin – (8007)
• Dose Optimization – (1804)
• Drugs / Biologics Not Covered Unless Approved Under Medical Necessity Review – Employer Group Plans: Standard Prescription Drug List and Performance Prescription Drug List – (1601)
• Drugs / Biologics Not Covered Unless Approved Under Medical Necessity Review – Employer Group Plans: Value Prescription Drug List and Advantage Prescription Drug List – (1602)
• Dupilumab – (1810)
• Filgrastim – (1611)
• Hereditary Angioedema (HAE) Therapy – (1019)
• Immune Globulin – (5026)
• Oncology Medications – (1403)
• Pegfilgrastim – (1320)
• Pharmacy Prior Authorization – (1407)
• Pulmonary Hypertension – (6121)
• Sacubitril-Valsartan (P0016)
• Teduglutide – (1318)
• Topical Doxepin – (P0054)
• Unassigned Drug or Biologic Code Medical Precertification – (1701)
• Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Use – (1206)

Click here to view the Cigna Medical & Pharmacy Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.